Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

108.61
+1.561.46%
Volume:323.20K
Turnover:35.12M
Market Cap:6.57B
PE:14.46
High:109.43
Open:106.94
Low:106.56
Close:107.05
Loading ...

Raymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
11 Jun

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial

TIPRANKS
·
11 Jun

Jazz Pharmaceuticals Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
11 Jun

Jazz Pharmaceuticals: FDA accepts sNDA for Zepzelca/ Atezolizumab combo

TIPRANKS
·
10 Jun

Jazz Pharmaceuticals' Zepzelca Combination Granted FDA Priority Review for First-Line Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer

Reuters
·
10 Jun

Zepzelca® (Lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

THOMSON REUTERS
·
10 Jun

Jazz Pharmaceuticals Plc - Pdufa Action Date Set for October 7, 2025

THOMSON REUTERS
·
10 Jun

Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025

Reuters
·
10 Jun

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (Calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution Treatment Outcomes in Narcolepsy at Sleep 2025

THOMSON REUTERS
·
10 Jun

Bruce C. Cozadd, Chairman & CEO, Reports Disposal of Common Shares of Jazz Pharmaceuticals plc

Reuters
·
05 Jun

TD Cowen Remains a Buy on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
03 Jun

Bank of America Securities Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
03 Jun

Jazz Pharmaceuticals Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
03 Jun

Jazz Pharmaceuticals Plc : Needham Raises Target Price to $202 From $200

THOMSON REUTERS
·
03 Jun

BRIEF-Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination

Reuters
·
03 Jun

Jazz Pharmaceuticals announces ‘positive’ results from Phase 3 IMforte study

TIPRANKS
·
03 Jun

Jazz Pharmaceuticals Announces Zepzelca® (Lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

THOMSON REUTERS
·
03 Jun

Jazz Pharmaceuticals Plc - Combination Therapy Reduces Disease Progression or Death Risk by 46%

THOMSON REUTERS
·
03 Jun

Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer

MT Newswires Live
·
03 Jun

Jazz Pharmaceuticals reports 15.2 months median PFS in Phase 2 trial

TIPRANKS
·
03 Jun